Novo Nordisk cuts price of weight-loss drug Wegovy in China
The semaglutide price reduction follows mounting competition in one of the largest obesity drug markets outside the United States.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 11 10:50 ETSource: Olhar Digital
The wire
- 01Novo Nordisk has lowered the price of Wegovy, its semaglutide obesity injection, in China, according to Olhar Digital.
- 02Pricing moves in China shape global reference pricing and signal how aggressively Novo will defend share against domestic and incretin rivals.
- 03The size of the cut, effective date and any accompanying reimbursement changes are not detailed in the report.
From the source
Read at olhardigital.com.brnovo nordisk cuts price of weight-loss drug wegovy in china
